Simplify Logo

Full-Time

Research Scientist II

Gene Editing, Durham NC

Confirmed live in the last 24 hours

ReCode Therapeutics

ReCode Therapeutics

51-200 employees

Develops genetic medicines with advanced delivery technology

Biotechnology
Healthcare

Compensation Overview

$120k - $130kAnnually

+ Cost of Living Adjustment for Remote Positions

Mid, Senior

Durham, NC, USA

Position is based in Durham; relocation provided for candidates not living in Durham.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
R
Requirements
  • PhD in molecular biology, cell biology, biological engineering or related discipline with 4 years of experience in postdoctoral research and/or industry.
  • Subject matter expertise, with a proven track record of publications/patents, in gene editing, with a broad knowledge of gene editing applications.
  • Hands-on experience using gene editing tools including next generation CRISPR systems (e.g. Prime or Base editors)
  • Deep expertise in analytic RNA or DNA assays to measure and analyze gene editing results.
  • Experience in utilizing bioinformatics tools and software for the analysis of gene editing readouts
  • Experience in mammalian cell and tissue culturing is required.
  • Experience with viral or non-viral delivery platforms, preferably lipid nanoparticles (LNPs) (recommended)
  • Understanding of lung biology and/or rare lung disease (recommended)
  • Excellent verbal and written communication skills, with proven ability to write reports and/or articles for publication.
  • Advanced knowledge of statistical and genome analytical tools (GraphPad, R, SnapGene)
  • Excellent project leadership skills in driving for results and innovation; ability to execute within a matrixed organization.
  • Extremely organized and able to efficiently manage your time and workflow, including skillfully prioritizing both long-term projects and day-to-day responsibilities.
  • Highly collaborative, team-oriented, and considerate of the needs of others.
  • Desire to work in a fast-paced environment and contribute to developing the next generation of gene editing.
Responsibilities
  • Lead, design, and execute experiments using next-generation gene editing and epigenome editing strategies with CRISPR-based tools and beyond.
  • Advance gene correction applications for therapeutic and non-viral platform discovery projects through the design, implementation/optimization, and execution of molecular biology, cell biology, and NGS-based assays.
  • Support the discovery of novel LNP delivery solutions through in vitro and in vivo gene editing screens.
  • Work with primary in vitro cell culture disease models of lung epithelial cells.
  • Generate, manage, evaluate, and maintain critical data in a highly organized manner, providing statistical analysis and troubleshooting where appropriate.
  • Analyze and present experimental data to a wide range of audiences.
  • Troubleshoot and dissect published literature to find novel solutions to resolve technical and/or biological hurdles.
  • Contribute as a key member of a cross functional drug discovery team that includes gene correction, primary human biology, pharmacology, computational biology, bioanalytical, toxicology and formulation capabilities.
  • Prepare SOPs, keep excellent electronic lab notebook and record keeping entries, and prepare reports and/or manuscripts for publication.
  • Manage one or more direct reports; mentor additions to the team.

ReCode Therapeutics offers a compelling work environment for those passionate about advancing the field of genetic medicine. The company's application of Selective Organ Targeting (SORT) lipid nanoparticle technology allows for precise delivery of genetic therapies beyond traditional liver targets, addressing rare diseases with groundbreaking approaches. Their focus on optimizing mRNA and gene correction further positions them as a forefront player in the biotechnology industry, making it an attractive place for innovative scientists and researchers looking to make a significant impact in medical science.

Company Stage

Series B

Total Funding

$521.8M

Headquarters

Dallas, Texas

Founded

2015

Growth & Insights
Headcount

6 month growth

2%

1 year growth

5%

2 year growth

53%
Simplify Jobs

Simplify's Take

What believers are saying

  • ReCode's recent $80 million Series A and additional $50 million Series B financing rounds indicate strong investor confidence and financial stability.
  • The appointment of experienced industry veterans like Dean J. Mitchell and John G. Matthews strengthens the company's leadership and clinical development capabilities.
  • Participation in high-profile conferences and strategic collaborations position ReCode as a thought leader in the genetic medicines space.

What critics are saying

  • The clinical-stage nature of ReCode's therapies means that they are still subject to the high risks and uncertainties of clinical trials.
  • The competitive landscape in genetic medicines and mRNA-based therapies is intense, with numerous well-funded competitors.

What makes ReCode Therapeutics unique

  • ReCode Therapeutics leverages its proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) platform for highly precise and targeted delivery of genetic medicines, setting it apart from competitors.
  • The company's focus on inhaled mRNA-based therapies for diseases like cystic fibrosis and primary ciliary dyskinesia addresses unmet needs in the respiratory disease market.
  • Strategic collaborations with leading gene editing companies like Intellia Therapeutics enhance ReCode's capabilities in developing novel genomic medicines.